الفهرس 
ERYTHROPOIETIN (EPO)Only 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Objective: The aim of this work is to estimate the prevalence of anti- Epo antibody in ESRD on regular hemodialysis patient at Suez Insurance Hospital and Ain Shams University Hospital, dialysis units and to assess the association between presence of anti Epo antibody and anemia and factors other than anti Epo antibody causing resistant anemia.
Patient and methods: 90 ESRD patients on regular hemodialysis receiving recombinant human erythropoietin hormone (rHuEPO); intra venous, sub cutaneous route were involved that will be randomly selected from Suez Insurance Hospital and Ain Shams University Hospital, dialysis units in the period from March to April 2017. Anti Epo antibody was measured for all patients according to anti-Epo antibody patients were divided into two groups (group A anti Epo antibody positive patients and group B anti Epo antibody negative patients).
Results: In our study the prevalence of anti-erythropoietin antibody was 45.6% (41 patients), anti Epo Ab positive patients have higher percentage of female 48.8% (20 patients) , anti Epo Ab positive patients have lower PTH and MCHC with median (IQR) 276.0 (251.5) and 29.7(2.50) respectively, anti Epo Ab positive patients have lower Hb, serum iron and TSAT with mean value (8.60±0.99), (52.91±16.30), and (22.62±8.27) respectively, anti Epo Ab positive patients 43.9% (18 patients) were on iron treatment and the route of Epo administration was mainly subcutaneous 58.5% (24 patients) and anti Epo Ab positive patients were receiving higher iron doses, higher Epo doses and high ERI with median (IQR) value100(100), 8000(4000), 11.27(6.56) respectively.
Conclusion: the present study revealed that anti-Epo antibodies were commonly present in prevalent hemodialysis patients who receiving Epo therapy. It is one of the causes of anemia resistance.